| Filing Date |
Description |
| 2012-12-31 |
As set forth more fully in the Stipulation, if the settlement becomes final, among other things, (i) the claims against the Defendants
will be dismissed with prejudice and released, by which the plaintiffs, the Company and its predecessors, successor ... |
| 2012-12-31 |
As set forth more fully in the Stipulation, if the settlement becomes final, among other things, (i) the claims against the Defendants
will be dismissed with prejudice and released, by which the plaintiffs, the Company and its predecessors, successor ... |
| 2012-12-31 |
As previously announced by Cell Therapeutics, Inc. (the “Company”), effective as of November 15, 2012, Daniel G. Eramian
separated from employment with the Company as its Executive Vice President, Corporate Communications. The Company agree ... |
| 2012-12-31 |
As previously announced by Cell Therapeutics, Inc. (the “Company”), effective as of November 15, 2012, Daniel G. Eramian
separated from employment with the Company as its Executive Vice President, Corporate Communications. The Company agree ... |
| 2012-12-28 |
The information provided pursuant to this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and sh ... |
| 2012-12-28 |
The information provided pursuant to this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and sh ... |
| 2012-12-07 |
(e)
Compensatory Arrangements of Certain Officers. On December 3, 2012, the Compensation Committee of the Board of Directors of Cell Therapeutics, Inc. (the “Company”) approved fiscal year-end cash incentive awards for 2012 for each of th ... |
| 2012-12-07 |
The amendment amends the definition of “Final Expiration Date” under the Rights Plan from the close of business on
the third anniversary of January 7, 2010, or the record date, to the close of business on December 3, 2015. The amendment als ... |
| 2012-12-07 |
The amendment amends the definition of “Final Expiration Date” under the Rights Plan from the close of business on
the third anniversary of January 7, 2010, or the record date, to the close of business on December 3, 2015. The amendment als ... |
| 2012-12-07 |
(e)
Compensatory Arrangements of Certain Officers. On December 3, 2012, the Compensation Committee of the Board of Directors of Cell Therapeutics, Inc. (the “Company”) approved fiscal year-end cash incentive awards for 2012 for each of th ... |
